Q-omics provides the consensus-scored SLC7A14 profile across patient tissues and cancer cell-line models. SLC7A14 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SLC7A14 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, SLC7A14 RNA expression shows 17,287 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, COAD, and GBM as cancer lineages where SLC7A14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC7A14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC7A14 survival associations across molecular data types. SLC7A14 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC7A14 RNA expression–survival associations across cancer types. High SLC7A14 expression shows unfavorable associations in KIRP, KIRC, THCA and READ, but favorable associations in ACC and LGG. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SLC7A14 RNA expression.
This table summarizes SLC7A14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SLC7A14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC7A14 shows lower tumor expression in COAD, KIRC, KICH, KIRP, BRCA and STAD. The COAD box plot shows higher SLC7A14 RNA expression in normal versus tumor tissue (log2 FC = −0.612, t-test p < 0.001).
This table shows molecular features associated with SLC7A14 in patient tissues and cancer cell lines. In patient samples, SLC7A14 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC7A14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BONE.
